<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Sci</journal-id><journal-id journal-id-type="iso-abbrev">Brain Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2399</journal-id><journal-id journal-id-type="pmc-domain">brainsci</journal-id><journal-id journal-id-type="publisher-id">brainsci</journal-id><journal-title-group><journal-title>Brain Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3425</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10046339</article-id><article-id pub-id-type="pmcid-ver">PMC10046339.1</article-id><article-id pub-id-type="pmcaid">10046339</article-id><article-id pub-id-type="pmcaiid">10046339</article-id><article-id pub-id-type="pmid">36979260</article-id><article-id pub-id-type="doi">10.3390/brainsci13030450</article-id><article-id pub-id-type="publisher-id">brainsci-13-00450</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Association between Antiepileptic Drugs and Incident Parkinson&#8217;s Disease among Patients Followed in German Primary Care Practices</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2124-7227</contrib-id><name name-style="western"><surname>Kostev</surname><given-names initials="K">Karel</given-names></name><xref rid="af1-brainsci-13-00450" ref-type="aff">1</xref><xref rid="af2-brainsci-13-00450" ref-type="aff">2</xref><xref rid="c1-brainsci-13-00450" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doege</surname><given-names initials="C">Corinna</given-names></name><xref rid="af3-brainsci-13-00450" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1071-1239</contrib-id><name name-style="western"><surname>Jacob</surname><given-names initials="L">Louis</given-names></name><xref rid="af4-brainsci-13-00450" ref-type="aff">4</xref><xref rid="af5-brainsci-13-00450" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5340-9833</contrib-id><name name-style="western"><surname>Smith</surname><given-names initials="L">Lee</given-names></name><xref rid="af6-brainsci-13-00450" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koyanagi</surname><given-names initials="A">Ai</given-names></name><xref rid="af4-brainsci-13-00450" ref-type="aff">4</xref><xref rid="af7-brainsci-13-00450" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gollop</surname><given-names initials="C">Celina</given-names></name><xref rid="af2-brainsci-13-00450" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schrag</surname><given-names initials="A">Anette</given-names></name><xref rid="af8-brainsci-13-00450" ref-type="aff">8</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cilia</surname><given-names initials="R">Roberto</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-brainsci-13-00450"><label>1</label>University Clinic, Philipps University, 35043 Marburg, Germany</aff><aff id="af2-brainsci-13-00450"><label>2</label>Epidemiology, IQVIA, 60549 Frankfurt, Germany</aff><aff id="af3-brainsci-13-00450"><label>3</label>Department of Pediatric Neurology, Center for Pediatrics and Adolescent Medicine, Central Hospital, 28211 Bremen, Germany</aff><aff id="af4-brainsci-13-00450"><label>4</label>Research and Development Unit, Parc Sanitari Sant Joan de D&#233;u, CIBERSAM, ISCIII, 42, Sant Boi de Llobregat, 08830 Barcelona, Spain</aff><aff id="af5-brainsci-13-00450"><label>5</label>Department of Physical Medicine and Rehabilitation, Lariboisi&#232;re-Fernand Widal Hospital, AP-HP, Paris Cit&#233; University, 75010 Paris, France</aff><aff id="af6-brainsci-13-00450"><label>6</label>Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge CB1 1PT, UK</aff><aff id="af7-brainsci-13-00450"><label>7</label>Instituci&#243; Catalana de Recerca i Estudis Avan&#231;ats (ICREA), Pg. Lluis Companys 23, 08830 Barcelona, Spain</aff><aff id="af8-brainsci-13-00450"><label>8</label>Neurology, University College London, London WC1N 3BG, UK</aff><author-notes><corresp id="c1-brainsci-13-00450"><label>*</label>Correspondence: <email>karel.kostev@iqvia.com</email>; Tel.: +49-(0)69-66-04-4878</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">432182</issue-id><elocation-id>450</elocation-id><history><date date-type="received"><day>13</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>01</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-30 07:10:11.133"><day>30</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="brainsci-13-00450.pdf"/><abstract><p>Background: The aim of this study was to analyze whether prescriptions of antiepileptic drugs (AEDs) are significantly associated with an increased incidence of Parkinson&#8217;s disease (PD) in the German population. Methods: This study used data from German primary care practices found in the Disease Analyzer database (IQVIA) and included all patients aged &#8805;18 years who were diagnosed with PD between January 2010 and December 2021 (index date). The controls were patients without PD matched (1:1) by age, sex, and pre-diagnostic observation time in years. Associations between AED prescriptions (any AED as well as separate evaluations for carbamazepine, lamotrigine, levetiracetam, sodium valproate, gabapentin, and pregabalin) and subsequent diagnosis of PD were examined using a logistic regression model adjusted for epilepsy, restless legs syndrome, and neuropathy diagnoses. Results: We identified 24,950 cases that were matched with 24,950 controls (mean age 75.2 years, 47.3% women). Diagnoses of epilepsy, restless legs syndrome, and neuropathy as well as AED prescription were significantly associated with an increased incidence of PD. In the multivariate analysis, incidence of PD was significantly associated with epilepsy (OR: 1.91; 95% CI: 1.69&#8211;2.15), restless legs syndrome (OR: 3.02; 95% CI: 2.73&#8211;3.34), and neuropathy (OR: 1.53; 95% CI: 1.44&#8211;1.62)), as well as the prescription of any AED (OR: 1.43; 95% CI: 1.33&#8211;1.53), sodium valproate (OR: 2.39; 95% CI: 1.84&#8211;3.11), gabapentin (OR: 1.36; 95% CI: 1.22&#8211;1.52), and pregabalin (OR: 1.28; 95% CI: 1.15&#8211;1.41)<bold>.</bold> Conclusion: Prescriptions of AEDs, including sodium valproate, gabapentin, and pregabalin, were associated with an increased risk of subsequent PD, even after adjustment for underlying diagnoses. Further studies are needed to confirm the present results.</p></abstract><kwd-group><kwd>antiepileptic drug</kwd><kwd>epilepsy</kwd><kwd>Parkinson&#8217;s disease</kwd><kwd>Germany</kwd></kwd-group><funding-group><funding-statement>This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-brainsci-13-00450"><title>1. Introduction</title><p>Parkinson&#8217;s disease (PD) is a neurodegenerative disorder with a prevalence of 1&#8211;2% among people aged over 60 years that increases with age; consequently, the prevalence estimations of PD may be affected by the under-diagnosis of PD among the most elderly people [<xref rid="B1-brainsci-13-00450" ref-type="bibr">1</xref>]. The incidence of PD has been increasing over the last few decades, rendering PD the fastest-growing neurological disorder worldwide [<xref rid="B2-brainsci-13-00450" ref-type="bibr">2</xref>]. The investigation of risk factors for PD has become an important research topic in recent years. For example, epilepsy has been found to be associated with a higher risk of subsequent PD onset [<xref rid="B3-brainsci-13-00450" ref-type="bibr">3</xref>,<xref rid="B4-brainsci-13-00450" ref-type="bibr">4</xref>]. Associations between different risk factors and pre-diagnostic presentations of PD have been reported for chronic diseases such as diabetes mellitus, hypertension, and depression, with a significant association found for epilepsy (Odds Ratio (OR), 2.50; 95% Confidence Intervals (CI), 1.63&#8211;3.83) [<xref rid="B4-brainsci-13-00450" ref-type="bibr">4</xref>]. Furthermore, some non-motor features of PD can predate the diagnosis of PD by several years.</p><p>Although the association between prescription medications and subsequent diagnosis of PD is of particular clinical relevance, it has not been comprehensively studied. Recently, Belete and colleagues reported that prescriptions of several antiepileptic drugs (AED) are significantly associated with an increased incidence of PD in the UK [<xref rid="B5-brainsci-13-00450" ref-type="bibr">5</xref>]. However, the association differed depending on the type of AED, being strongest for valproate (OR: 3.82; 95% CI: 2.41&#8211;6.05) and weakest (and statistically non-significant) for carbamazepine (OR: 1.43; 95% CI: 0.97&#8211;2.11). The authors also conducted analyses in a hospital setting and studied the four most commonly prescribed AEDs in the UK, but these findings may not be generalizable to other AEDs or other countries [<xref rid="B5-brainsci-13-00450" ref-type="bibr">5</xref>]. Therefore, we examined whether these associations can be replicated in German primary care practices.</p></sec><sec sec-type="methods" id="sec2-brainsci-13-00450"><title>2. Methods</title><sec id="sec2dot1-brainsci-13-00450"><title>2.1. Database</title><p>This study used data from German primary care practices found in the Disease Analyzer database (IQVIA). Details of the methodology behind this database have been published previously [<xref rid="B6-brainsci-13-00450" ref-type="bibr">6</xref>]. In brief, the Disease Analyzer database contains data on demographic variables, diagnoses, and prescriptions from general and specialized practices in Germany. </p><p>The quality of the data is assessed every month based on several criteria (e.g., completeness of documentation and linkage between diagnoses and prescriptions). Practices included in the database are selected based on the yearly statistics published by the German Medical Association, which include information on physician&#8217;s age, specialty group, community size category, and German federal state. Prior research has shown that the Disease Analyzer database is representative of all practices in Germany [<xref rid="B7-brainsci-13-00450" ref-type="bibr">7</xref>].</p><p>German law allows for the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study, which contains no directly identifiable data. Therefore, no waiver of ethical approval was obtained from an Institutional Review Board (IRB) or ethics committee. The authors had no access to any identifying information at any time during the analysis of the data.</p></sec><sec id="sec2dot2-brainsci-13-00450"><title>2.2. Study Population</title><p>The study population included all patients aged &#8805;18 years with a diagnosis of PD (ICD-10 code: G20) made between January 2010 and December 2021 (index date) who had been registered in the database for at least one year prior to the index date. This latter inclusion criterion was chosen to ensure that no patients recently registered in the database who had an existing diagnosis of PD were included. </p><p>Controls were patients without PD who were matched (1:1) by age, sex, and their pre-diagnostic observation time in years. For individuals without PD, the index date was a randomly selected visit date between January 2010 and December 2021. A flow diagram of study participants is shown in <xref rid="brainsci-13-00450-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec2dot3-brainsci-13-00450"><title>2.3. Statistical Analyses</title><p>Demographic and clinical characteristics of cases and controls after 1:1 propensity-score matching were evaluated using the Wilcoxon signed-rank test for continuous variables, the McNemar test for categorical variables with two categories, and the Stuart&#8211;Maxwell test for categorical variables with more than two categories. Associations between AED prescriptions (any AED as well as separate analyses for carbamazepine, lamotrigine, levetiracetam, sodium valproate, gabapentin, and pregabalin) and subsequent diagnosis of PD (dependent variable) were examined using logistic regression. As antiepileptic medications can be prescribed for other conditions that may themselves be associated with subsequent diagnosis of PD, such as epilepsy, restless legs syndrome, and painful diabetic or toxic and drug-induced neuropathy, we also examined the association between the conditions and these diagnoses. ICD-10 codes were used for epilepsy (ICD-10: G40), restless legs syndrome (ICD-10: G25.8), and diabetic/toxic/drug-induced neuropathy (ICD-10: G62, E10.4, E11.4, E14.4) diagnoses. Multivariate logistic regression models included all AEDs examined and the diagnoses listed above. </p><p>We performed sensitivity analyses including only AEDs prescribed at least 12 months before the index date or at least 36 months before the index date. <italic toggle="yes">p</italic>-values &lt; 0.01 were considered statistically significant. </p></sec></sec><sec sec-type="results" id="sec3-brainsci-13-00450"><title>3. Results</title><p>We identified 24,950 cases, which were matched with 24,950 controls. The mean (standard deviation, SD) age on the index date was 75.2 (10.5) years and 47.3% of patients were female. The majority of patients were aged between 71&#8211;80 (41.7%) or &gt;80 (33.3%), with just 9.3% aged &#8804;60 years. On average, both the cases and controls had a pre-observation time of 7.8 (SD 5.0) years prior to the index date (<xref rid="brainsci-13-00450-t001" ref-type="table">Table 1</xref>). </p><p>In the univariable regression analysis, epilepsy (OR: 2.39; 95% CI: 1.14&#8211;2.67, <italic toggle="yes">p</italic> &lt; 0.001), restless legs syndrome (OR: 3.62; 95% CI: 3.28&#8211;4.00, <italic toggle="yes">p</italic> &lt; 0.001), and drug-induced/toxic/diabetic neuropathy (OR: 1.84; 95% CI: 1.74&#8211;1.95, <italic toggle="yes">p</italic> &lt; 0.001) were all associated with subsequent diagnosis of PD. Each AED was also significantly associated with subsequent PD. In the multivariable regression analysis, which was adjusted for epilepsy, restless legs syndrome, and neuropathy, the prescription of any AED was significantly associated with an increased incidence of PD (OR: 1.43; 95% CI: 1.33&#8211;1.53, <italic toggle="yes">p</italic> &lt; 0.001). Some 12.1% of the PD cases versus 6.5% of the controls had received at least one AED prescription. The strongest association was seen for sodium valproate (OR: 2.39; 95% CI: 1.84&#8211;3.11, <italic toggle="yes">p</italic> &lt; 0.001), followed by gabapentin (OR: 1.36; 95% CI: 1.22&#8211;1.52, <italic toggle="yes">p</italic> &lt; 0.001) and pregabalin (OR: 1.28; 95% CI: 1.15&#8211;1.41, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="brainsci-13-00450-t002" ref-type="table">Table 2</xref>). </p><p>However, after adjustment for the diagnoses specified above and other AEDs, there was no longer any association between lamotrigine, carbamazepine, and levetiracetam and PD. Epilepsy diagnosis (OR: 1.91; 95% CI: 1.69&#8211;2.15, <italic toggle="yes">p</italic> &lt; 0.001), restless legs syndrome (OR: 3.02; 95% CI: 2.73&#8211;3.34, <italic toggle="yes">p</italic> &lt; 0.001), and neuropathy (OR: 1.53; 95% CI: 1.44&#8211;1.62, <italic toggle="yes">p</italic> &lt; 0.001) remained associated with PD after adjustment for AEDs (<xref rid="brainsci-13-00450-t002" ref-type="table">Table 2</xref>).</p><p>The sensitivity analyses showed that the adjusted associations between gabapentin (OR: 1.40; 95% CI: 1.24&#8211;1.60, when prescribed at least 12 months before the index date, and OR: 1.41; 95% CI: 1.14&#8211;1.74, when prescribed at least 36 months before the index date), pregabalin (OR: 1.49; 95% CI: 1.33&#8211;1.67, when prescribed at least 12 months prior to the index date, and OR: 1.98; 95% CI: 1.54&#8211;1.2.53, when prescribed at least 36 months prior to the index date) and PD were confirmed in both sensitivity analyses. The odds ratio for sodium valproate was still significantly increased when the drug was prescribed 12 months prior to the index date or earlier (OR: 1.24; 95% CI: 1.60&#8211;2.87); however, the adjusted OR was no longer significant (OR: 1.11; 95% CI: 0.70&#8211;1.75, <italic toggle="yes">p</italic> = 0.663) when sodium valproate was prescribed 36 months prior to the index date or earlier (<xref rid="brainsci-13-00450-t003" ref-type="table">Table 3</xref>).</p></sec><sec sec-type="discussion" id="sec4-brainsci-13-00450"><title>4. Discussion</title><p>In this case control study, prescriptions of all AEDs investigated were associated with a subsequent diagnosis of PD. In the multivariable regression analyses, even when adjusting for underlying diagnoses of epilepsy, restless legs syndrome, and neuropathic disorders, sodium valproate, gabapentin, and pregabalin were significantly and positively associated with incident PD. Although the association between each AED and subsequent PD became weaker after adjustment for the diagnoses these AEDs were prescribed for, the associations were still strong and significant. </p><p>Overall, our results confirm the findings of Belete et al. [<xref rid="B5-brainsci-13-00450" ref-type="bibr">5</xref>], with similar ORs for any AED, sodium valproate, and carbamazepine in both studies. Although Belete et al. also found significant positive associations for lamotrigine and levetiracetam, we did not find a significant association for either drug in the multivariate analysis. This is likely due to an additional adjustment for underlying diagnoses, which we found to be independently associated with incident PD. Furthermore, our study found that gabapentin and pregabalin, which were not examined in the previous study, were also associated with the onset of PD, even after adjustment. Whilst the studies differed in terms of AED prescription rates, which were 4.3% in the PD cases in the study of Belete et al. and 12.1% in our study, the results of our study confirm and expand those of Belete et al. in a German collective. Whilst we cannot rule out the possibility that the diagnoses for which AEDs are prescribed may differ in Germany and the UK, or at least that the proportions of AED prescriptions differ in both countries, the results of both studies are broadly similar [<xref rid="B8-brainsci-13-00450" ref-type="bibr">8</xref>]. In addition, we have expanded the findings by adding new associations for further AEDs and examining the differential contribution of underlying diagnoses and AED prescription.</p><p>While it is well known that parkinsonism is induced by sodium valproate, it is less commonly described as an adverse effect of other AEDs [<xref rid="B9-brainsci-13-00450" ref-type="bibr">9</xref>,<xref rid="B10-brainsci-13-00450" ref-type="bibr">10</xref>]. Pacheco-Paez et al. reported a significant association between gabapentin and pregabalin and parkinsonism: among 5,653,547 case safety reports from the World Health Organization individual case safety report database, 4925 parkinsonism reports were found for patients taking pregabalin and 4881 for those receiving gabapentin [<xref rid="B11-brainsci-13-00450" ref-type="bibr">11</xref>]. In rare cases, parkinsonism cases were also reported in patients treated with lamotrigine [<xref rid="B12-brainsci-13-00450" ref-type="bibr">12</xref>]. No parkinsonism cases have yet been reported among patients treated with levetiracetam [<xref rid="B13-brainsci-13-00450" ref-type="bibr">13</xref>]. Indeed, this drug can also be used for the management of levodopa-induced dyskinesias in patients with Parkinson&#8217;s disease [<xref rid="B14-brainsci-13-00450" ref-type="bibr">14</xref>]. Levetiracetam was also the only AED that was not associated with PD in the multivariate analysis in our study. Notably, our sensitivity analysis suggested that whilst the association between gabapentin and pregabalin and incident PD may be a long-term side effect, parkinsonism associated with sodium valproate is a short-term side effect since prescriptions issued in the recent past but not in the longer term were associated with subsequent PD.</p><p>In our study, epilepsy, restless legs syndrome, and neuropathy were each independently associated with PD. Associations between epilepsy and PD [<xref rid="B3-brainsci-13-00450" ref-type="bibr">3</xref>,<xref rid="B4-brainsci-13-00450" ref-type="bibr">4</xref>] and between restless legs syndrome and PD [<xref rid="B15-brainsci-13-00450" ref-type="bibr">15</xref>,<xref rid="B16-brainsci-13-00450" ref-type="bibr">16</xref>] have already been reported in the past. The prevalence of restless legs syndrome is increased in PD patients compared to the general population, and both epilepsy and restless legs syndrome have been reported as an early clinical feature of PD [<xref rid="B16-brainsci-13-00450" ref-type="bibr">16</xref>,<xref rid="B17-brainsci-13-00450" ref-type="bibr">17</xref>]. Furthermore, pain is a common non-motor symptom of PD, and neuropathy is increased in PD patients, including in the prodromal phase [<xref rid="B7-brainsci-13-00450" ref-type="bibr">7</xref>,<xref rid="B18-brainsci-13-00450" ref-type="bibr">18</xref>,<xref rid="B19-brainsci-13-00450" ref-type="bibr">19</xref>]. Interpretations of previous associations between PD and these diagnoses, particularly epilepsy, have been cautious due to the confounding effects of AEDs such as sodium valproate. However, our analysis suggests that epilepsy and AEDs each contribute to the risk factor of incident PD.</p><p>The strengths of this study are its inclusion of more than 24,000 PD patients and examination of a number of different AEDs in a primary care population. Furthermore, we were able to adjust for the presence of underlying diagnoses that have been reported to be associated with incident PD. However, the study is also subject to several limitations. First, as we used electronic medical records from primary care practices, we did not have information on how the PD cases were diagnosed (i.e., diagnostic criteria or assessment tools). The diagnosis of PD relied on ICD-10 codes alone, and no data were available on symptoms (e.g., tremor, bradykinesia, muscle stiffness, and others). Second, both epilepsy and PD may have been diagnosed and treated in specialized practices and hospitals, and some of the related data could have been undocumented in the electronic medical records of general practitioners in the Disease Analyzer database. Third, no data were available on smoking status and alcohol use that would allow these variables to be taken into consideration as PD risk factors. </p></sec><sec sec-type="conclusions" id="sec5-brainsci-13-00450"><title>5. Conclusions</title><p>This retrospective study including adults followed in general practices in Germany found that not only epilepsy, restless legs syndrome, and neuropathy but also AEDs including sodium valproate, gabapentin, and pregabalin were associated with an increased risk of subsequent PD. Further studies on these associations among older adults, especially investigations conducted in other countries, are needed to confirm the present results.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, K.K.; methodology, K.K.; formal analysis, K.K.; writing&#8212;original draft preparation, K.K., A.S. and C.D.; writing&#8212;review and editing, C.G., L.J., L.S. and A.K.; supervision, A.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. </p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author on reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-brainsci-13-00450"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tysnes</surname><given-names>O.B.</given-names></name><name name-style="western"><surname>Storstein</surname><given-names>A.</given-names></name></person-group><article-title>Epidemiology of Parkinson&#8217;s disease</article-title><source>J. Neural. Transm.</source><year>2017</year><volume>124</volume><fpage>901</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1007/s00702-017-1686-y</pub-id><pub-id pub-id-type="pmid">28150045</pub-id></element-citation></ref><ref id="B2-brainsci-13-00450"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorsey</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Sherer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>B.R.</given-names></name></person-group><article-title>The Emerging Evidence of the Parkinson Pandemic</article-title><source>J. Park. Dis.</source><year>2018</year><volume>8</volume><issue>(Suppl. S1)</issue><fpage>S3</fpage><lpage>S8</lpage><pub-id pub-id-type="doi">10.3233/JPD-181474</pub-id><pub-id pub-id-type="pmid">30584159</pub-id><pub-id pub-id-type="pmcid">PMC6311367</pub-id></element-citation></ref><ref id="B3-brainsci-13-00450"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heilbron</surname><given-names>K.</given-names></name><name name-style="western"><surname>Noyce</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Fontanillas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alipanahi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nalls</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>P.</given-names></name><collab>23andMe Research Team</collab></person-group><article-title>The Parkinson&#8217;s phenome-traits associated with Parkinson&#8217;s disease in a broadly phenotyped cohort</article-title><source>NPJ Park. Dis.</source><year>2019</year><volume>5</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1038/s41531-019-0077-5</pub-id><pub-id pub-id-type="pmid">30937360</pub-id><pub-id pub-id-type="pmcid">PMC6437217</pub-id></element-citation></ref><ref id="B4-brainsci-13-00450"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simonet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bestwick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jitlal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ben-Joseph</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marrium</surname><given-names>S.</given-names></name><name name-style="western"><surname>Robson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Assessment of risk factors and early presentations of Parkinson disease in primary care in a diverse UK population</article-title><source>JAMA Neurol.</source><year>2022</year><volume>79</volume><fpage>359</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.0003</pub-id><pub-id pub-id-type="pmid">35254398</pub-id><pub-id pub-id-type="pmcid">PMC8902684</pub-id></element-citation></ref><ref id="B5-brainsci-13-00450"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belete</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Simonet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bestwick</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Noyce</surname><given-names>A.J.</given-names></name></person-group><article-title>Association Between Antiepileptic Drugs and Incident Parkinson Disease in the UK Biobank</article-title><source>JAMA Neurol.</source><year>2022</year><volume>80</volume><fpage>183</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.4699</pub-id><pub-id pub-id-type="pmid">36574240</pub-id><pub-id pub-id-type="pmcid">PMC9857018</pub-id></element-citation></ref><ref id="B6-brainsci-13-00450"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathmann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bongaerts</surname><given-names>B.</given-names></name><name name-style="western"><surname>Carius</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kruppert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kostev</surname><given-names>K.</given-names></name></person-group><article-title>Basic characteristics and representativeness of the German Disease Analyzer database</article-title><source>Int. J. Clin. Pharmacol. Ther.</source><year>2018</year><volume>56</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.5414/CP203320</pub-id><pub-id pub-id-type="pmid">30168417</pub-id></element-citation></ref><ref id="B7-brainsci-13-00450"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajabally</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Martey</surname><given-names>J.</given-names></name></person-group><article-title>Neuropathy in Parkinson disease: Prevalence and determinants</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>1947</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31823a0ee4</pub-id><pub-id pub-id-type="pmid">22049200</pub-id></element-citation></ref><ref id="B8-brainsci-13-00450"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamer</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kostev</surname><given-names>K.</given-names></name></person-group><article-title>Usage of antiepileptic drugs in different diseases in Germany&#8212;A retrospective study</article-title><source>Epilepsy Behav.</source><year>2020</year><volume>111</volume><fpage>107210</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2020.107210</pub-id><pub-id pub-id-type="pmid">32554234</pub-id></element-citation></ref><ref id="B9-brainsci-13-00450"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brugger</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Besag</surname><given-names>F.M.</given-names></name></person-group><article-title>Valproate-Associated Parkinsonism: A Critical Review of the Literature</article-title><source>CNS Drugs</source><year>2016</year><volume>30</volume><fpage>527</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1007/s40263-016-0341-8</pub-id><pub-id pub-id-type="pmid">27255404</pub-id></element-citation></ref><ref id="B10-brainsci-13-00450"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tampi</surname><given-names>R.R.</given-names></name></person-group><article-title>Valproic acid-induced parkinsonism in the elderly: A comprehensive review of the literature</article-title><source>Am. J. Geriatr. Pharm.</source><year>2011</year><volume>9</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.amjopharm.2011.09.002</pub-id><pub-id pub-id-type="pmid">21993183</pub-id></element-citation></ref><ref id="B11-brainsci-13-00450"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco-Paez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Montastruc</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chebane</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lapeyre-Mestre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Renoux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montastruc</surname><given-names>J.L.</given-names></name></person-group><article-title>Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study</article-title><source>Mov. Disord.</source><year>2020</year><volume>35</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1002/mds.27876</pub-id><pub-id pub-id-type="pmid">31633228</pub-id></element-citation></ref><ref id="B12-brainsci-13-00450"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rissardo</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Fornari Caprara</surname><given-names>A.L.</given-names></name></person-group><article-title>Lamotrigine-Associated Movement Disorder: A Literature Review</article-title><source>Neurol. India</source><year>2021</year><volume>69</volume><fpage>1524</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.4103/0028-3886.333440</pub-id><pub-id pub-id-type="pmid">34979637</pub-id></element-citation></ref><ref id="B13-brainsci-13-00450"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;enz-Farret</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tijssen</surname><given-names>M.A.J.</given-names></name><name name-style="western"><surname>Eliashiv</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fasano</surname><given-names>A.</given-names></name></person-group><article-title>Antiseizure Drugs and Movement Disorders</article-title><source>CNS Drugs</source><year>2022</year><volume>36</volume><fpage>859</fpage><lpage>876</lpage><comment>Erratum in <italic toggle="yes">CNS Drugs</italic><bold>2022</bold>, <italic toggle="yes">36</italic>, 859&#8211;876</comment><pub-id pub-id-type="doi">10.1007/s40263-022-00937-x</pub-id><pub-id pub-id-type="pmid">35861924</pub-id></element-citation></ref><ref id="B14-brainsci-13-00450"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stathis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Konitsiotis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tagaris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.</given-names></name></person-group><article-title>VALID-PD Study Group. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson&#8217;s disease</article-title><source>Mov. Disord.</source><year>2011</year><volume>26</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/mds.23355</pub-id><pub-id pub-id-type="pmid">21412833</pub-id></element-citation></ref><ref id="B15-brainsci-13-00450"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Borreguero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Odin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>C.</given-names></name></person-group><article-title>Restless legs syndrome and PD: A review of the evidence for a possible association</article-title><source>Neurology</source><year>2003</year><volume>61</volume><issue>(Suppl. S3)</issue><fpage>S49</fpage><lpage>S55</lpage><pub-id pub-id-type="doi">10.1212/WNL.61.6_suppl_3.S49</pub-id><pub-id pub-id-type="pmid">14504380</pub-id></element-citation></ref><ref id="B16-brainsci-13-00450"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso-Navarro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ag&#250;ndez</surname><given-names>J.A.G.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Jim&#233;nez</surname><given-names>F.J.</given-names></name></person-group><article-title>Association between restless legs syndrome and other movement disorders</article-title><source>Neurology</source><year>2019</year><volume>92</volume><fpage>948</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000007500</pub-id><pub-id pub-id-type="pmid">31004074</pub-id></element-citation></ref><ref id="B17-brainsci-13-00450"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schrag</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bohlken</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dammertz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Teipel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Akmatov</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>B&#228;tzing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holstiege</surname><given-names>J.</given-names></name></person-group><article-title>Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease</article-title><source>JAMA Neurol.</source><year>2023</year><volume>80</volume><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.3902</pub-id><pub-id pub-id-type="pmid">36342675</pub-id><pub-id pub-id-type="pmcid">PMC9641600</pub-id></element-citation></ref><ref id="B18-brainsci-13-00450"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>A.R.M.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>A.Q.</given-names></name></person-group><article-title>Peripheral neuropathy in Parkinson&#8217;s disease</article-title><source>Neurol. Sci.</source><year>2020</year><volume>41</volume><fpage>2691</fpage><lpage>2701</lpage><pub-id pub-id-type="doi">10.1007/s10072-020-04407-4</pub-id><pub-id pub-id-type="pmid">32358706</pub-id></element-citation></ref><ref id="B19-brainsci-13-00450"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gr&#252;newald</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Hadjivassiliou</surname><given-names>M.</given-names></name></person-group><article-title>Peripheral neuropathy in idiopathic Parkinson&#8217;s disease: A systematic review</article-title><source>J. Neurol. Sci.</source><year>2017</year><volume>378</volume><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2017.05.023</pub-id><pub-id pub-id-type="pmid">28566165</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="brainsci-13-00450-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram concerning study participants.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="brainsci-13-00450-g001.jpg"/></fig><table-wrap position="float" id="brainsci-13-00450-t001" orientation="portrait"><object-id pub-id-type="pii">brainsci-13-00450-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study sample (after 1:1 matching).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PD Cases (<italic toggle="yes">n</italic> = 24,950)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Non-PD Controls (<italic toggle="yes">n</italic> = 24,950)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value <sup>1</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean age (standard deviation)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.2 (10.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.2 (10.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age &#8804; 60 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.3</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age 61&#8211;70 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age 71&#8211;80 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age &gt; 80 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.3</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-diagnostic observation time in years, mean (standard deviation) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.8 (5.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.8 (5.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td></tr></tbody></table><table-wrap-foot><fn><p>Data are given as percentages unless otherwise stated. PD = Parkinson&#8217;s disease. <sup>1</sup>&#160;<italic toggle="yes">p</italic>-values were obtained using Wilcoxon signed-rank tests for continuous age and the average number of medical consultations per year during the follow-up time, the Stuart&#8211;Maxwell test for categorical age, and McNemar tests for comorbidities.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="brainsci-13-00450-t002" orientation="portrait"><object-id pub-id-type="pii">brainsci-13-00450-t002_Table 2</object-id><label>Table 2</label><caption><p>Association between antiepileptic drugs and incident Parkinson&#8217;s disease among patients followed in German primary care practices.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AED Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cases (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Controls (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">COR for PD (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AOR for PD (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Any AED</td><td align="center" valign="middle" rowspan="1" colspan="1">12.1</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.00 (1.87&#8211;2.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43 (1.33&#8211;1.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gabapentin</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96 (1.76&#8211;2.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36 (1.22&#8211;1.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pregabalin</td><td align="center" valign="middle" rowspan="1" colspan="1">5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.87 (1.70&#8211;2.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 (1.15&#8211;1.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carbamazepine</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46 (1.23&#8211;1.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 (0.73&#8211;1.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.169</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sodium valproate</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.78 (2.95&#8211;4.85)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.39 (1.84&#8211;311)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Levetiracetam</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.79 (1.46&#8211;2.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03 (0.83&#8211;1.29)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.803</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lamotrigine</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.89 (1.35&#8211;2.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 (0.73&#8211;1.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.804</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.39 (1.14&#8211;2.67)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.91 (1.69&#8211;2.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Restless legs syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.62 (3.28&#8211;4.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">3.02 (2.73&#8211;3.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.84 (1.74&#8211;1.95)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.53 (1.44&#8211;1.62)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>COR: Crude odds ratio; AOR: Adjusted odds ratio. All multivariable analyses were adjusted for diagnoses of epilepsy, restless legs syndrome, and neuropathy as well as other AEDs.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="brainsci-13-00450-t003" orientation="portrait"><object-id pub-id-type="pii">brainsci-13-00450-t003_Table 3</object-id><label>Table 3</label><caption><p>Association between antiepileptic drugs prescribed in the past and incident Parkinson&#8217;s disease among patients followed in German primary care practices.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">AED Drug</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AEDs Prescribed at Least 12 Months Prior to Index Date </th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AEDs Prescribed at Least 36 Months Prior to Index Date </th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AOR for PD (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AOR for PD (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Any AED</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50 (1.39&#8211;1.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43 (1.26&#8211;1.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gabapentin</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 (1.24&#8211;1.60)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 (1.14&#8211;1.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pregabalin</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49 (1.33&#8211;1.67) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.98 (1.54&#8211;2.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carbamazepine</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 (0.73&#8211;1.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.214</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80 (0.62&#8211;1.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sodium valproate</td><td align="center" valign="middle" rowspan="1" colspan="1">2.14 (1.60&#8211;2.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (0.70&#8211;1.75)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.663</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Levetiracetam</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.70&#8211;1.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.530</td><td align="center" valign="middle" rowspan="1" colspan="1">2.00 (0.80&#8211;4.96)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.137</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lamotrigine</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33 (0.87&#8211;2.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.196</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (0.51&#8211;2.86)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.668</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="middle" rowspan="1" colspan="1">1.99 (1.77&#8211;2.23)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.21 (1.97&#8211;2.47)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Restless legs syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">3.20 (2.90&#8211;3.54)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">3.27 (2.96&#8211;3.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.58 (1.49&#8211;1.68)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.65 (1.55&#8211;1.75)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>AOR, Adjusted odds ratio. All multivariable analyses were adjusted for diagnoses of epilepsy, restless legs syndrome, and neuropathy and other AEDs.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>